Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2006 Mar:188:255-63.
doi: 10.1192/bjp.188.3.255.

Rechallenge with clozapine following leucopenia or neutropenia during previous therapy

Louisa R Dunk  1 , Linda J Annan, Christopher D Andrews
Affiliations
Multicenter Study

Rechallenge with clozapine following leucopenia or neutropenia during previous therapy

Louisa R Dunk et al. Br J Psychiatry. 2006 Mar.

Abstract

Background: Further treatment with clozapine is contraindicated in any patient who has previously experienced leucopenia or neutropenia during clozapine therapy.

Aims: To investigate the results of such a rechallenge in 53 patients.

Method: An analysis was made of the demographic, haematological and outcome data of patients in the UK and Ireland who were rechallenged with clozapine following leucopenia or neutropenia during previous clozapine therapy.

Results: Of 53 patients who were rechallenged, 20 (38%) experienced a further blood dyscrasia. In 17 of these 20 patients (85%) the second blood dyscrasia was more severe (P<0.001), in 12 (60%) it lasted longer (P=0.0368) and in 17 (85%) it occurred more quickly on rechallenge (P<0.001). Of the original 53 patients, 55% (29 patients) are still receiving clozapine.

Conclusions: No clear risk factor for repeat blood dyscrasias was identified. Despite this, after risks and benefits have been considered, rechallenge may well be justified in some patients.

PubMed Disclaimer

Comment in

Publication types